2893 A. Efficacy and Safety of Aztreonam-Avibactam for the Treatment of Serious Infections Due to Gram-Negative Bacteria, Including Metallo-β-Lactamase-Producing Pathogens: Phase 3 REVISIT Study

Yehuda Carmeli(Tel Aviv University), Joseph W. Chow(Pfizer (United States)), Rienk Pypstra(Pfizer (United States)), Minggui Wang(Fudan University), Francis F. Arhin(Pfizer (United States)), Julián Torre Cisneros(Hospital Universitario Reina Sofía), Georgios Daikos(Laiko General Hospital of Athens), Joanne L. Leaney(Pfizer (United Kingdom)), O. V. Pyptіuk(Ivano-Frankivsk National Medical University), Firdevs Aksoy(Karadeniz Technical University), Mical Paul(Technion – Israel Institute of Technology), Jose-Miguel Cisneros(Hospital Universitario Reina Sofía), Michele Wible, Yongjie Zhao(Union General Hospital), Lu Liang(Fudan University), Rosa-María Jiménez Rodríguez(Instituto de Biomedicina de Sevilla), Halley Rogers(Pfizer (United States)), Ivan Titov(Ivano-Frankivsk National Medical University), Alison Luckey(Global Antibiotic Research & Development Partnership), George Singer(UCLA Medical Center), Gang Chen(The First Hospital of Kunming), Illia Gumenchuk(Kyiv City Clinical Oncology Center)
Open Forum Infectious Diseases
November 27, 2023
Cited by 25


Related Papers